Deal-making Metrics - Quantitative Trends in Partnering Transactions

The life sciences industry has never seen such an intensity of deal-making, especially that of licensing, than in the past six years. Some of the reasons for this are quite evident: growing pharmaceutical companies have greater pipeline needs, a spate of patent expiries threatens future revenues and research and development (R&D) externalisation has become central to the innovation strategies of cash-rich companies.

Synergy or Vanity: the Appetite for Pharma Mega-Mergers

The late 1990s and early years of the current decade saw a number of mega-mergers between companies, which defined the current shape of the pharmaceutical industry, and have established a hierarchy of companies commonly referred to as `big pharma'. In recent years, however, there have been no mega-mergers, suggesting that the industry might have lost its appetite for such deals. The publicly explained rationale for these mergers might differ between transactions, 

Finding and Executing Pharma Licensing Opportunities

It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma are in the attractive position that they get thousands of unsolicited pharma licensing offers from small R&D companies every year and they have ample capacity to conduct due diligence on the promising candidates and partners.